JP2009544675A - 置換されたイミダゾロン誘導体、製造方法及び使用 - Google Patents

置換されたイミダゾロン誘導体、製造方法及び使用 Download PDF

Info

Publication number
JP2009544675A
JP2009544675A JP2009521318A JP2009521318A JP2009544675A JP 2009544675 A JP2009544675 A JP 2009544675A JP 2009521318 A JP2009521318 A JP 2009521318A JP 2009521318 A JP2009521318 A JP 2009521318A JP 2009544675 A JP2009544675 A JP 2009544675A
Authority
JP
Japan
Prior art keywords
methyl
butyl
oxy
carboxy
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544675A5 (OSRAM
Inventor
ブーイ，エディット
マソン，クリストフ
ベルトラン，カリーヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfit SA
Original Assignee
Genfit SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit SA filed Critical Genfit SA
Publication of JP2009544675A publication Critical patent/JP2009544675A/ja
Publication of JP2009544675A5 publication Critical patent/JP2009544675A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009521318A 2006-07-24 2007-07-24 置換されたイミダゾロン誘導体、製造方法及び使用 Pending JP2009544675A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0606752A FR2903984B1 (fr) 2006-07-24 2006-07-24 Derives d'imidazolones substitues, preparation et utilisations
PCT/FR2007/051716 WO2008012470A2 (fr) 2006-07-24 2007-07-24 Derives d'imidazolones substitues, preparation et utilisations

Publications (2)

Publication Number Publication Date
JP2009544675A true JP2009544675A (ja) 2009-12-17
JP2009544675A5 JP2009544675A5 (OSRAM) 2010-07-22

Family

ID=37843186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521318A Pending JP2009544675A (ja) 2006-07-24 2007-07-24 置換されたイミダゾロン誘導体、製造方法及び使用

Country Status (16)

Country Link
US (1) US20100004159A1 (OSRAM)
EP (1) EP2049107A2 (OSRAM)
JP (1) JP2009544675A (OSRAM)
KR (1) KR20090038469A (OSRAM)
CN (1) CN101522192A (OSRAM)
AU (1) AU2007279135A1 (OSRAM)
BR (1) BRPI0715326A2 (OSRAM)
CA (1) CA2658625A1 (OSRAM)
EA (1) EA200900211A1 (OSRAM)
FR (1) FR2903984B1 (OSRAM)
IL (1) IL196671A0 (OSRAM)
MX (1) MX2009000900A (OSRAM)
NO (1) NO20090348L (OSRAM)
NZ (1) NZ575011A (OSRAM)
WO (1) WO2008012470A2 (OSRAM)
ZA (1) ZA200901268B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017524704A (ja) * 2014-08-13 2017-08-31 シャンハイ シェイルテック テクノロジー カンパニー リミテッド カルボン酸化合物、その製造方法および使用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AU2011232657A1 (en) * 2010-03-26 2012-09-27 Merck Sharp & Dohme Corp. Novel spiro imidazolone derivatives as glucagon receptor antagonists, compositions, and methods for their use
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8633231B2 (en) 2010-07-13 2014-01-21 Merck Sharp & Dohme Corp. Substituted imidazolones, compositions containing such compounds and methods of use
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
BR112015032370B1 (pt) 2013-06-27 2022-08-30 Lg Chem, Ltd Derivado de biarila, composição, e, método para preparar uma composição
CA2934257C (en) 2013-12-17 2022-06-07 Janssen Pharmaceutica Nv Imidazolin-5-one derivative useful as fasn inhibitors for the treatment of cancer
CN104177298B (zh) * 2014-09-18 2018-10-02 湘潭大学 4,4-二取代-4,5-二氢-1h–咪唑-5-酮、衍生物及其合成方法
EP3324952B1 (en) 2015-07-17 2020-12-16 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
JP2018526411A (ja) * 2015-09-11 2018-09-13 ラクオリア創薬株式会社 Ｔｒｐｍ８拮抗剤としてのイミダゾリノン誘導体
KR102375929B1 (ko) 2016-03-31 2022-03-16 온크터널 테라퓨틱스, 인코포레이티드. 인돌린 유사체 및 이의 용도
CA3030054A1 (en) 2016-07-15 2018-01-18 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair
CN113121394B (zh) * 2019-12-30 2022-11-08 中国药科大学 一种苯氧乙酸类衍生物的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
JP2005517643A (ja) * 2001-11-30 2005-06-16 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体アゴニスト
JP2006515566A (ja) * 2002-08-10 2006-06-01 ベセスダ ファーマシューティカルズ， インコーポレイテッド 体液貯溜、浮腫またはうっ血性心不全を誘発しない新規ｐｐａｒリガンド

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005517643A (ja) * 2001-11-30 2005-06-16 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体アゴニスト
JP2006515566A (ja) * 2002-08-10 2006-06-01 ベセスダ ファーマシューティカルズ， インコーポレイテッド 体液貯溜、浮腫またはうっ血性心不全を誘発しない新規ｐｐａｒリガンド
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017524704A (ja) * 2014-08-13 2017-08-31 シャンハイ シェイルテック テクノロジー カンパニー リミテッド カルボン酸化合物、その製造方法および使用

Also Published As

Publication number Publication date
CN101522192A (zh) 2009-09-02
EP2049107A2 (fr) 2009-04-22
IL196671A0 (en) 2009-11-18
FR2903984A1 (fr) 2008-01-25
NO20090348L (no) 2009-04-24
EA200900211A1 (ru) 2009-06-30
WO2008012470A2 (fr) 2008-01-31
ZA200901268B (en) 2010-04-28
CA2658625A1 (fr) 2008-01-31
WO2008012470A3 (fr) 2008-03-20
FR2903984B1 (fr) 2008-10-03
NZ575011A (en) 2011-12-22
MX2009000900A (es) 2009-06-18
KR20090038469A (ko) 2009-04-20
AU2007279135A1 (en) 2008-01-31
BRPI0715326A2 (pt) 2013-08-13
US20100004159A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
JP2009544675A (ja) 置換されたイミダゾロン誘導体、製造方法及び使用
KR101416262B1 (ko) 치환된 1, 3-디페닐프로판 유도체, 그 제조 및 용도
CN101605775B (zh) 取代的3-苯基-1-(苯基噻吩基)丙-1-酮类以及3-苯基-1-(苯基呋喃基)丙-1-酮类的衍生物、制备以及用途
US20110195993A1 (en) Ppar agonist compounds, preparation and uses
EA001680B1 (ru) Производные бензопирана, обладающие антагонистическим действием в отношении лейкотриена
Kasuga et al. Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) δ-selective agonists
JP5258761B2 (ja) Ｃｏｘ−２阻害剤としてのフェニル酢酸誘導体
Class et al. Patent application title: SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES Inventors: Edith Bouey (Lorgies, FR) Christophe Masson (Lambersart, FR) Karine Bertrand (Frelinghien, FR) Assignees: GENFIT

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130702